Executive Chairman, Novocure Ltd.
Bill is the Executive Chairman of Novocure Ltd., a company commercializing a new therapeutic modality for solid tumors using low intensity electric fields. Recently, Novocure received FDA approval to treat recurrent Glioblastoma (GBM), the most common and deadly form of brain cancer. In 2002, Bill co-founded healthcare venture capital firm WFD Ventures. Prior to founding WFD, Bill served as an executive of Johnson & Johnson where he was a member of J&J’s Medical Devices and Diagnostics Group Operating Committee with responsibility for licensing, acquisitions & strategy.
Bill is a graduate of MIT and Harvard Business School. He serves as a member of the Dean’s Advisory Board of Harvard Business School; Harvard Business School’s Healthcare Advisory Board; and the MIT Corporation’s Visiting Committee for Undergraduate Education.